Cenexi regulatory delays
Unannounced ANSM inspection at Fontenay caused production loss and corrective measures, pushing EBITDA breakeven to Q3 FY26. Further regulatory actions could delay recovery.
GLAND / Q3-FY25 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Volume recovery in US base business
Base business revenue declined 8% YoY due to volume degrowth in key products like Enoxaparin. Recovery depends on timing of shipments and new product ramp-up.
Saudi tender revenue deferral
The Saudi tender shipment was pushed out by a quarter, impacting Q3 revenue. Further delays could affect near-term ROW growth.
Chinese competition and tariff uncertainty
Chinese players control 50-60% of Heparin API supply. While US tariffs may benefit Gland, raw material dependence on China remains a risk.